Russian Doctor Warns Chest Pain While Moving Could Signal Heart Attack
Russian Doctor Warns Chest Pain While Moving Could Signal Heart Attack
Russian Doctor Warns Chest Pain While Moving Could Signal Heart Attack
A well-known Russian doctor has warned that chest pain during movement could signal an oncoming heart attack. Alexander Myasnikov, a physician and TV host, highlighted the symptom in recent comments. He stressed the importance of recognising such signs early to prevent serious health risks.
Myasnikov explained that pain, especially in the heart, should not be ignored when it occurs while walking or exerting effort. He advised that anyone experiencing this kind of discomfort should stop and rest immediately. The doctor also pointed out that not all heart attacks come with obvious pain, which can lead to delays in seeking help.
He emphasised that some people may not realise the severity of their condition if they do not feel intense pain. This lack of awareness can result in dangerous delays in treatment. His remarks were shared widely, though no specific medical expert was named in connection with Russia’s Channel One report on the topic.
The warning comes as part of broader efforts to raise awareness about heart attack symptoms. Myasnikov’s advice focuses on quick action when unusual heart pain appears. Recognising these signs early could help save lives by prompting faster medical intervention.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?